Context: The role of percutaneous coronary intervention in the treatment of multivessel coronary artery disease (CAD) is still controversial and widely discussed. Aim: The aim of this study was to examine the incidence of clinical outcomes after utilization of Indolimus, biodegradable polymer coated sirolimus-eluting stent (SES), in multivessel coronary stenting in an unselected patient population. Settings and Design: From April-2012 to June-2014, patients with multivessel (≥2 vessels) disease were examined in the retrospective, nonrandomized, observational, multicenter MULTIDES study. Materials and Methods: A total of 151 patients, exclusively treated with Indolimus SES in multivessel, were included in the study. The study was conducted in accordance with the Declaration of Helsinki and country-specific regulatory requirements. All patients signed informed consent form. Statistical Analysis Used: Continuous variables are presented as mean ± standard deviation and categorical variables as counts and percentages. All data were analyzed using Statistical Package for Social Sciences program. Results: The mean age was 53.7 ± 10.7 years; male gender represented 108 (71.5%) patients. A total of 314 Indolimus stents were implanted. Clinical follow-up was performed at 30-day, at 6-month, and at 9-month. The primary endpoint, major adverse cardiac events (MACEs) at 9-month follow-up, occurred in 5 (3.3%) patients, consisting of 1 (0.7%) cardiac death, 2 (1.3%) myocardial infarction, 2 (1.3%) target lesion revascularization, 0 (0%) target vessel revascularization, and 0 (0%) stent thrombosis. Conclusion: The present study describes that Indolimus implantation is safe and effective treatment in multivessel CAD, showing low rates of MACEs during 9-month follow-up.
INTRODUCTION
Multivessel disease (MVD) in comparison to single vessel disease relates to a worsened prognosis and is evidenced in up to half of the patients referred for urgent angiography. [1, 2] The optimal revascularization treatment for patients with MVD remains a subject of debate. [3] However, with recent advancements in endovascular technology and adjunctive pharmacotherapy, multiple-vessel percutaneous coronary intervention (PCI) is now feasible and is associated with outcomes similar to those of single vessel or staged procedures. [4] We, therefore, conducted this observational, multicenter, nonrandomized study to examine the safety and efficacy of the Indolimus sirolimus-eluting stent (SES) in real-world patients with multiple (≥2) coronary lesions. Polavarapu, et al.: MULTIDES study 
MATERIALS AND METHODS

Study design and patient population
From April-2012 to June-2014, a total of 151 patients, exclusively treated with Indolimus SES in multivessel (≥2 vessels), were examined in the retrospective, nonrandomized, observational, multicenter MULTIDES study. The study was conducted in accordance with the declaration of Helsinki and country-specific regulatory requirements. All patients signed informed consent form which was reviewed and approved by the Institutional Review Board or Independent Ethics Committee.
The inclusion criteria for the study were: 1. Patients of age 18 years or above.
Patients who had stable or unstable angina or acute recent
myocardial infarction (MI) and 3. Patients who were undergoing coronary intervention with MVD.
The patients were excluded if they refused to give written informed consent or if they had any allergy to aspirin, clopidogrel, ticlopidine, heparin, cobalt-chromium (Co-Cr), sirolimus, or polymers used in a study stent.
Description of the study stent
The Indolimus biodegradable polymer coated sirolimus-eluting coronary stent involves L605 (Co-Cr) alloy as its stent platform. The biodegradable polymer gives it a strut thickness of 60 µm and drug load of 1.4 µg/mm 2 . About 70% of drug is released within 7 days, and remaining drug is released over a period of 48 days [ Figure 1 ]. The drug is released within 7 weeks after the stent implantation from the polymeric layers coated onto the surface of the stent. The biodegradable polymeric film is a blend of different biodegradable polymers-Poly L-Lactide, 50/50 Poly DL Lactide-co-Glycolide, and Polyvinylpyrrolidone, which undergoes hydrolysis. This process takes approximately 9-12 months after which all the polymer degrades naturally and excretes from the body in the form of their metabolites.
The average coating thickness of Indolimus stent is between 5 and 6 µm. The Indolimus stent is available in various lengths and diameters.
Interventional procedure and adjunctive medication
All patients received a loading dose of 300 mg of aspirin and clopidogrel (300 mg) or prasugrel (60 mg) or ticagrelor (two tablets of 90 mg each). The procedural anticoagulation was brought about either with heparin or bivalirudin. However, the intraprocedural administration of glycoprotein IIb/IIIainhibitor was at the investigator's volition. The procedure was performed according to the standard treatment guidelines of each participating center. All the patients received dual antiplatelet therapy (aspirin 75-300 mg/day indefinitely and clopidogrel 75 mg/day or prasugrel 10 mg/day or ticagrelor 90 mg twice daily for at least 6 months) after the procedure.
Endpoints of the study
The primary endpoint of the study was major adverse cardiac events (MACEs), which is a conglomerate of cardiac death, MI (Q-wave and non-Q-wave) and target lesion revascularization (TLR), target vessel revascularization (TVR), and stent thrombosis (ST). These endpoints were observed during in-hospital stay, at 30-day, 6-month, and 9-month follow-up. MACE will be evaluated as secondary endpoints at 12 and 24 months.
Definition of endpoints and clinical events
Procedural success was defined in terms of in-hospital MACE. MACE is composed of cardiac death, MI, TLR, and TVR. Death can be cardiac or noncardiac death. Any death due to undetermined cause was reported as cardiac death. Q-wave MI was considered when there was development of new Q-wave of more than 0.04 s in two or more adjoining leads along with an increase in cardiac markers such as Troponin I or T, creatine kinase, or MB isoform. Non-Q-wave MI was considered when there was more than 3 times elevation in creatine kinase levels along with elevation in MB isoform and Troponin markers T or I without development of new Q-waves. [5] TLR was considered when there was stenosis in treated segment (5 mm proximal and 5 mm distal edges). TVR was considered when there was stenosis in any segment of the treated vessel. ST was considered acute when it occurred within 24 h, subacute when it occurred between 1 and 30 days, and late when it occurred after 30 days. [5] "Definite" ST was defined by symptoms suggestive of an acute coronary syndrome and angiographic or pathologic confirmation of ST. "Probable" ST was described as unexplained death within 30 days or target vessel MI without angiographic confirmation of ST. "Possible" ST was defined as any unexplained death after 30 days. [6] Follow-up
All patients were subjected to in-hospital, 30-day, 6-month, and 9-month follow-up. Clinical follow-up was scheduled by telephone communication or clinic visit at 30-day, 6-month, and 9-month. Follow-up data were collected relating to the clinical status, any hospitalization and occurrence of any adverse events.
Further follow-up is scheduled to be taken at 12-month and at 24-month.
Statistical analysis
Continuous variables are presented as mean ± standard deviation and categorical variables as counts and percentages. The event-free survival curve was calculated according to the Kaplan-Meier method [ Figure 2 ]. All data were analyzed using the Statistical Package for Social Sciences (IBM SPSS Statistics; Chicago, IL, USA) program, version 15.
RESULTS
Baseline demographics and lesion characteristics
A total of 151 patients were enrolled in the study. The basic demographic details of the patients are outlined in Patients with two and three diseased vessels were 137 (90.7%) and 14 (9.3%), respectively. A total of 314 Indolimus stents (two, three, and four stents in 92.7%, 6.6%, and 0.7% of patients, respectively) were implanted at index procedure (2.1 stents/ patients) with an average diameter and total stent length of 3.1 ± 0.4 mm and 26.8 ± 9.2 mm, respectively. The lesion and angiographic procedural details are outlined in Table 2 .
Clinical outcomes
The primary endpoint, MACE at 9-month follow-up, occurred in five (3.3%) patients, consisting of 1 (0.7%) cardiac death, 2
(1.3%) MI, 2 (1.3%) TLR, 0 (0%) TVR, and 0 (0%) ST. The detailed clinical outcomes of the study are outlined in Table 3 .
Long-term follow-up of the study would further confirm safety and efficacy.
DISCUSSION
The optimal strategy for the treatment of patients with multivessel coronary artery disease (CAD) has been a matter of conflict. [3] Figure 2: Cumulative event-free survival curve at 9-month follow-up Before the advent of drug-eluting stent (DES), the preferable and superior treatment for MVD was coronary artery bypass grafting (CABG) as compared to bare metal stents (BMS). This was highlighted in Arterial Revascularization Therapies Study (ARTS) and ERACI II trials [7, 8] and also in other studies. The superiority of CABG was due to lower incidences of revascularizations and MACE. However, when the era of DES commenced, these trials as ARTS II and ERACI III further compared CABG with DES in MVD using the same historical control groups. [9, 10] The results of these trials showed a better performance of DES, even though contemporary candidates treated with DES were at higher clinical and anatomical risk than their surgical counterparts.
Overall, four prospective randomized trials have been published comparing CABG with DES in MVD. The results in terms of death, MI, and stroke were similar (P = 0.56) in these trials. [11] As the years passed, the disparity in the need for repeat revascularization following CABG and PCI, which favored surgery, has decreased. [12] Multivessel DES implantation is likely to be considered on a growing proportion of patients who were traditionally referred for CABG surgery. However, the magnitude of this shift has been difficult to quantify and prognosticate. [13] There have been incessant attempts to find new approaches for the development of DES techniques and devices, from the antecedent durable polymer-based DES toward the biodegradable polymerbased DES, which led to a decrease in the occurrence of adverse events with time. [14, 15] Earlier studies had been performed using Indolimus as the study stent. In the "All-Comers" study, MACE at 6-month was 3.4%, [16] other studies that involved diabetic, and acute MI patients reported MACE to be 4.1% and 4.2%, respectively. [17, 18] These studies depict the consistent efficacy and safety of Indolimus regardless of patient characteristics and complexities. In this study, patient population had higher rates of hypertension (37.1%) and diabetes (38.4%), 26.5% were smokers, and unstable angina (29.1%). The combination of these factors along with an average of 2.1 stents per patient makes the study population atypically complex. In spite of such complications, cumulative MACE at 9-month follow-up was found to be only 3.3% which consisted of one case of cardiac death, two cases of MI, and two cases of TLR.
There have been many recent studies that reflect the preferability of DES in complex anatomical conditions. In a real-world cohort study, [19] comparison of the results of following approaches were performed: BMS only, DES and BMS in the same patient (hybrid stenting), and DES only. [20] Previous studies state that multivessel SES implantation can be safely performed on patients with complex CAD, [21] and it was also identified that independent predictors for consequent cardiac events or repeat revascularization following stent interventions; unstable angina, prior angioplasty or CABG, diabetes mellitus, and reference vessel diameter were associated with clinical events in a multivariate model. Interestingly, the number of vessels treated or stents used did not associate with adverse cardiac end points. [22] Thus, despite of more complex profile and clinical risk factors in this study, there were fewer incidences of MACE which prove the safety and efficacy of Indolimus SES in patients with multivessel, complex CAD. 
